Hepatorenal Syndrome (HRS)

1. Overview

Hepatorenal Syndrome (HRS) represents one of the most challenging and life-threatening complications of advanced chronic liver disease, characterised by functional renal failure in the absence of structural kidney damage. Despite the kidneys being histologically normal, profound renal vasoconstriction leads to progressive decline in glomerular filtration rate (GFR) and renal perfusion. [1,2]

HRS occurs almost exclusively in the context of decompensated cirrhosis with ascites, though it can occasionally complicate acute liver failure and alcoholic hepatitis. The syndrome carries an extremely poor prognosis, with untreated HRS-AKI (formerly Type 1 HRS) associated with median survival of less than 2 weeks and 90% mortality at 3 months. [3] Modern vasopressor-based therapy can reverse HRS in 40-50% of cases, but definitive cure requires liver transplantation. [4]

The International Club of Ascites (ICA) redefined HRS nomenclature in 2015, replacing the traditional Type 1/Type 2 classification with HRS-AKI (acute kidney injury) and HRS-NAKI (non-acute kidney injury, previously chronic kidney disease). This aligns terminology with the broader acute kidney injury literature and better reflects the dynamic nature of renal dysfunction in cirrhosis. [5]

Understanding HRS requires appreciation of the complex haemodynamic derangements in cirrhosis, where paradoxical splanchnic vasodilation coexists with systemic vasoconstriction, creating a "forward flow" problem that starves vital organs including the kidneys. Recognition and early intervention are critical, as delayed diagnosis significantly worsens outcomes.

---

2. Epidemiology

Incidence and Prevalence

HRS is a relatively common complication of advanced cirrhosis, with cumulative incidence estimates suggesting:

• 18-20% of hospitalised patients with cirrhosis and ascites develop HRS within 1 year. [6]
• 40% cumulative probability at 5 years following first onset of ascites. [7]
• Among patients admitted with acute-on-chronic liver failure (ACLF), 22-34% present with or develop HRS-AKI. [8]

Demographics

• Age: Median age 50-60 years, reflecting typical age of decompensated cirrhosis. [10]
• Sex: Male predominance (approximately 2:1), consistent with higher rates of alcohol-related liver disease and viral hepatitis in men. [11]
• Aetiology of cirrhosis:
  • "Alcohol-related liver disease: 40-50%"
  • "Hepatitis C: 20-30%"
  • "NASH (Non-alcoholic steatohepatitis): Increasing (15-20%)"
  • "Hepatitis B: 10-15% (geographic variation)"

Risk Factors

Several clinical factors increase risk of HRS development:

Precipitating Events (60-80% of cases):

1. Spontaneous Bacterial Peritonitis (SBP): Most common trigger. 25-30% of SBP episodes complicated by HRS despite antibiotic therapy. [9]
2. Large Volume Paracentesis (LVP): Without albumin replacement. Risk 15-20% without albumin cover. [12]
3. Gastrointestinal Bleeding: Particularly variceal haemorrhage with hypovolaemia.
4. Sepsis: Any bacterial infection, not just SBP.
5. Over-diuresis: Aggressive diuretic therapy causing intravascular depletion.
6. Nephrotoxic Medications: NSAIDs, aminoglycosides, radiocontrast.

Baseline Patient Factors:

• Advanced liver disease (Child-Pugh Class C, MELD score > 20)
• Pre-existing renal impairment
• Hyponatraemia (serum Na less than 130 mmol/L)
• Low mean arterial pressure (less than 80 mmHg)
• Absence of hepatomegaly (reflects small, end-stage liver)

Geographic and Temporal Trends

• Western populations show increasing NASH-related cirrhosis as aetiology for HRS.
• Improved management of viral hepatitis (HCV cure, HBV suppression) may reduce HRS incidence long-term.
• Enhanced awareness and earlier use of vasopressors appears to improve outcomes in recent cohorts. [13]

---

3. Aetiology & Pathophysiology

The Peripheral Arterial Vasodilation Hypothesis

The pathophysiology of HRS is complex but can be understood through the peripheral arterial vasodilation hypothesis, which explains the paradoxical haemodynamic changes in advanced cirrhosis. [14]

Stage 1: Portal Hypertension and Splanchnic Vasodilation

1. Portal Hypertension Development: Cirrhosis increases intrahepatic vascular resistance due to:

   • Architectural distortion (fibrosis, nodular regeneration)
   • Increased hepatic vascular tone (endothelial dysfunction)
   • Portal pressure rises (normal 5-10 mmHg → > 12 mmHg in cirrhosis)

2. Splanchnic Vasodilation: Portal hypertension triggers massive vasodilation in the splanchnic (gut) circulation via:

   • Nitric Oxide (NO): Increased production from vascular endothelium and bacterial translocation
   • Prostacyclin (PGI₂): Vasodilator prostaglandins
   • Carbon Monoxide (CO): Generated by heme oxygenase
   • Endocannabinoids: CB1 receptor activation
   • The splanchnic bed can sequester up to 20-30% of cardiac output. [14,15]

Stage 2: Effective Arterial Blood Volume Depletion

Despite total blood volume being normal or increased (due to ascites and sodium retention), the effective arterial blood volume (EABV) is reduced because:

• Blood pools in the vasodilated splanchnic bed
• Arterial baroreceptors in carotid sinus and aortic arch detect "underfilling"
• Systemic arterial pressure falls

Stage 3: Compensatory Neurohumoral Activation

The body interprets low EABV as hypovolaemic shock and activates compensatory systems:

Renin-Angiotensin-Aldosterone System (RAAS):

• Renin secretion from juxtaglomerular apparatus
• Angiotensin II generation → renal vasoconstriction (preferentially afferent arteriole)
• Aldosterone release → sodium and water retention

Sympathetic Nervous System (SNS):

• Increased noradrenaline release
• Systemic vasoconstriction (except splanchnic bed, which is maximally dilated)
• Increased cardiac output (initially)

Antidiuretic Hormone (ADH/Vasopressin):

• Released from posterior pituitary
• Water retention → dilutional hyponatraemia
• V1 receptor-mediated vasoconstriction

Stage 4: Renal Vasoconstriction and Hypoperfusion

The kidneys are "collateral damage" in this compensatory response:

• Angiotensin II, noradrenaline, and vasopressin cause intense renal afferent arteriole vasoconstriction
• Reduced renal blood flow (can drop to 50% of normal)
• Reduced GFR → oliguria, azotaemia, rising creatinine
• Kidneys are structurally normal but functionally shut down

Key Concept: If kidneys from an HRS patient are transplanted into a patient with normal liver function, they work perfectly. This proves HRS is functional, not structural renal failure. [16]

Exam Detail: ### Molecular Mechanisms of Renal Vasoconstriction

Intrarenal Haemodynamics:

• Normal GFR depends on balance between afferent arteriole (brings blood in) and efferent arteriole (drains blood out)
• In HRS:
  • "Afferent arteriole: Intense vasoconstriction (↓ blood flow in)"
  • "Efferent arteriole: Relative preservation (angiotensin II effect)"
  • "Net effect: Reduced glomerular capillary pressure → ↓ GFR"

Vasoconstrictor Dominance:

• Vasoconstrictors: Angiotensin II, noradrenaline, endothelin-1, leukotrienes
• Vasodilators: Nitric oxide, prostacyclin (but renal synthesis impaired in cirrhosis)
• In HRS, vasoconstrictor activity overwhelms vasodilator capacity

Prostaglandin Dependence:

• In early cirrhosis, kidneys maintain perfusion via prostaglandin synthesis (PGE₂, PGI₂)
• NSAIDs block prostaglandin synthesis → precipitate HRS
• This explains why NSAIDs are absolutely contraindicated in cirrhosis

Additional Mechanisms:

• Bacterial Translocation: Gut-derived endotoxins and bacterial products amplify inflammation and worsen vasodilation
• Cardiac Dysfunction: Cirrhotic cardiomyopathy reduces cardiac output reserve
• Adrenal Insufficiency: Relative adrenal insufficiency in critical illness worsens vasodilation

Triggers and Precipitants

HRS rarely occurs spontaneously. Precipitating events cause acute worsening of haemodynamics or further reduce EABV:

---

4. Clinical Presentation

HRS-AKI vs HRS-NAKI Classification

The ICA-AKI criteria (2015) replaced the older Type 1/Type 2 terminology: [5]

Symptoms

HRS itself is often asymptomatic initially. Patients present with symptoms of:

Underlying Cirrhosis:

• Jaundice (icterus)
• Abdominal distension (ascites)
• Confusion (hepatic encephalopathy)
• Weakness, fatigue

AKI-Related:

• Oliguria: Reduced urine output (less than 400-500 mL/day in severe cases)
• Anuria: Complete cessation (rare, suggests advanced stage)
• Nausea, anorexia
• Oedema (peripheral, sacral)

Precipitant Symptoms:

• Fever, abdominal pain (if SBP is trigger)
• Melaena, haematemesis (if GI bleed)

Metabolic Derangements:

• Hyponatraemia: Due to water retention (ADH excess). Serum Na often less than 130 mmol/L
• Uraemic symptoms (late): Confusion, pericarditis (very advanced)

Signs

General Inspection:

• Cachexia, muscle wasting (sarcopenia)
• Jaundice
• Fetor hepaticus (sweet, musty breath)

Haemodynamic Status:

• Hypotension: Mean arterial pressure often less than 80 mmHg
• Tachycardia: Compensatory
• Warm peripheries: Paradoxical vasodilation (contrast with cool peripheries in classic shock)

Stigmata of Chronic Liver Disease:

• Spider naevi, palmar erythema
• Gynaecomastia, testicular atrophy
• Caput medusae (dilated periumbilical veins)
• Dupuytren's contracture, leukonychia, clubbing

Abdominal Examination:

• Ascites: Shifting dullness, fluid thrill
• Hepatomegaly (may be absent in shrunken cirrhotic liver)
• Splenomegaly (portal hypertension)

Fluid Status:

• Intravascular Depletion: Low JVP, postural hypotension
• Total Body Fluid Overload: Peripheral oedema, ascites
• This paradox ("dry arteries, wet tissues") is characteristic

Uraemic Signs (Late):

• Pericardial rub (uraemic pericarditis)
• Asterixis (hepatic encephalopathy + uraemia)

---

5. Differential Diagnosis

AKI in cirrhosis has multiple causes. HRS is a diagnosis of exclusion after ruling out:

1. Pre-Renal AKI (Hypovolaemia)

Key Features:

• History of volume loss (vomiting, diarrhoea, over-diuresis, bleeding)
• Improves with volume expansion (2 days albumin trial)

Distinguishing from HRS:

• HRS does NOT improve with fluids (by definition)

2. Acute Tubular Necrosis (ATN)

Causes in Cirrhosis:

• Prolonged hypotension (septic shock)
• Nephrotoxins (aminoglycosides, contrast, NSAIDs)
• Rhabdomyolysis

Distinguishing Features:

• Urine sodium > 20-40 mmol/L (kidneys cannot reabsorb Na if tubules damaged)
• FeNa > 1-2% (fractional excretion of sodium)
• Urine sediment: Muddy brown casts, epithelial cells
• History of hypotension or toxin exposure

3. Intrinsic Renal Disease

Glomerulonephritis:

• Hepatitis B/C-associated membranoproliferative GN
• IgA nephropathy (alcohol)
• Cryoglobulinaemia (HCV)

Distinguishing Features:

• Proteinuria > 500 mg/day
• Haematuria (dysmorphic RBCs, red cell casts)
• Active urine sediment

4. Post-Renal AKI (Obstruction)

Rare in cirrhosis but consider:

• Prostate enlargement (men)
• Abdominal malignancy

Diagnosis: Renal ultrasound shows hydronephrosis

5. Sepsis-Related AKI

Common in cirrhosis. Sepsis can cause:

• Pre-renal (hypotension)
• ATN (prolonged shock)
• HRS (SBP trigger)

Approach: Treat infection aggressively first. If AKI persists despite infection control + volume expansion → likely HRS.

Summary Table

---

6. Investigations

Diagnostic Criteria for HRS-AKI (ICA-AKI 2015)

All criteria must be met: [5]

1. Cirrhosis with ascites
2. AKI according to ICA-AKI criteria:
   • Increase in serum creatinine ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, OR
   • Increase in serum creatinine ≥50% from baseline (within prior 7 days)
3. No response to diuretic withdrawal and volume expansion:
   • Stop diuretics
   • Give albumin 1 g/kg/day (maximum 100 g/day) for 2 consecutive days
   • Creatinine does NOT improve
4. Absence of shock (systolic BP > 90 mmHg without vasopressors)
5. No current or recent nephrotoxic drugs (NSAIDs, aminoglycosides, iodinated contrast)
6. No structural kidney disease:
   • Proteinuria less than 500 mg/day
   • No microhaematuria (> 50 RBCs/high power field)
   • Normal renal ultrasound

Essential Baseline Investigations

Serum Tests

Urine Tests

Calculation of FeNa (Fractional Excretion of Sodium):

FeNa (%) = [(Urine Na × Plasma Cr) / (Plasma Na × Urine Cr)] × 100

• FeNa less than 1%: Pre-renal or HRS (kidneys avidly retaining Na)
• FeNa > 2%: ATN (tubules cannot reabsorb Na)

Imaging

Renal Ultrasound:

• Purpose: Exclude obstruction and structural disease
• Findings in HRS: Normal-sized kidneys, no hydronephrosis, normal cortical thickness
• If kidneys are small and scarred → chronic kidney disease, NOT HRS

Ascitic Tap (Diagnostic Paracentesis):

• Mandatory in all patients with ascites + AKI to exclude SBP

Chest X-Ray:

• Assess for pulmonary oedema (albumin overload)
• Exclude infection

Severity Scoring

MELD Score (Model for End-Stage Liver Disease):

• Predicts mortality in cirrhosis
• Used for transplant priority

MELD = 3.78×ln(bilirubin mg/dL) + 11.2×ln(INR) + 9.57×ln(creatinine mg/dL) + 6.43

• Creatinine is capped at 4.0 mg/dL
• HRS significantly increases MELD score → higher transplant priority

AKIN/KDIGO Staging:

Exam Detail: ### Advanced/Research Investigations

Biomarkers (Not Routine):

Renal Resistive Index (Doppler US):

• Measures resistance in renal arteries
• Elevated (> 0.70) in HRS due to vasoconstriction
• Not specific, not routinely used

---

7. Management

Principles of Management

1. Identify and treat precipitant (SBP, bleeding, over-diuresis)
2. Stop nephrotoxins and diuretics
3. Volume expansion trial (albumin)
4. Vasopressor therapy (terlipressin + albumin)
5. Bridge to transplant (definitive cure)
6. Consider RRT (if vasopressors fail or not suitable)

Management Algorithm

        AKI IN CIRRHOSIS WITH ASCITES
        (Rising Creatinine)
                ↓
    1. STOP DIURETICS & NEPHROTOXINS
    2. SCREEN FOR INFECTION (SBP)
       - Diagnostic paracentesis
       - Blood/urine cultures
    3. TREAT INFECTION IF PRESENT
       - Cefotaxime 2g IV TDS (SBP)
       - PLUS Albumin 1.5g/kg day 1, 1g/kg day 3
                ↓
    VOLUME EXPANSION TRIAL
    - IV Albumin 1 g/kg/day × 2 days
    - Maximum 100 g/day
                ↓
    CREATININE IMPROVED AFTER 48h?
      ┌──────────┴──────────┐
     YES                   NO
      ↓                     ↓
   PRE-RENAL AKI       REVIEW CRITERIA
   (Not HRS)           - Shock present? → Treat shock
   Continue albumin    - Nephrotoxins? → Stop & reassess
   Monitor             - Obstruction on US? → Relieve
                       - Proteinuria > 500mg? → Nephrology
                           ↓
                       IF ALL EXCLUDED:
                       **HRS-AKI DIAGNOSED**
                           ↓
                   INITIATE VASOPRESSOR THERAPY
                   (If no contraindications)
                           ↓
              ┌────────────┴────────────┐
        TERLIPRESSIN                NORADRENALINE
        (Ward-based)               (ICU setting)
        1-2mg IV Q4-6h              0.5-3 mg/h IV
        + Albumin 20-40g/day        + Albumin 20-40g/day
              ↓                           ↓
        MONITOR RESPONSE (Daily Cr)
              ↓
        RESPONSE TO TREATMENT?
        (Cr ↓ to less than 133 μmol/L or less than 1.5 mg/dL)
      ┌──────────┴──────────┐
     YES                   NO
      ↓                     ↓
   COMPLETE RESPONSE    PARTIAL/NO RESPONSE
   - Continue Rx        - Escalate dose
   - Monitor recurrence - Consider RRT
   - List for transplant- Assess transplant suitability
      ↓                     ↓
   LIVER TRANSPLANT     SIMULTANEOUS LIVER-KIDNEY
   (If AKI less than 4-6 weeks)  (If AKI > 4-6 weeks or dialysis > 8 weeks)
                            ↓
                        OR PALLIATIVE CARE
                        (If not transplant candidate)

1. General Measures

Stop Nephrotoxic Drugs and Diuretics

Mandatory withdrawal:

• Diuretics: Spironolactone, furosemide (worsen intravascular depletion)
• NSAIDs: Block renal prostaglandins → precipitate HRS
• Aminoglycosides: Direct tubular toxicity (gentamicin)
• ACE inhibitors/ARBs: Worsen hypotension, reduce GFR
• Radiocontrast: Use sparingly, ensure adequate hydration

Treat Precipitating Factors

Spontaneous Bacterial Peritonitis (SBP):

• Antibiotics: Cefotaxime 2g IV TDS (or ceftriaxone 2g IV OD) for 5 days [9]
• Albumin: 1.5 g/kg IV within 6 hours, then 1 g/kg on day 3
  • Reduces HRS incidence from 30% to 10% in SBP [9]

Gastrointestinal Bleeding:

• Volume resuscitation (blood products, avoid over-transfusion)
• Variceal bleeding protocol (terlipressin, antibiotics, endoscopy)

Large Volume Paracentesis:

• Always give albumin: 6-8 g per litre ascites removed (if > 5L removed) [12]
• Prevents post-paracentesis circulatory dysfunction

2. Volume Expansion Trial (Diagnostic and Therapeutic)

Albumin 20% Solution:

• Dose: 1 g/kg/day IV for 2 days (maximum 100 g/day)
• Purpose:
  • "Diagnostic: Distinguishes pre-renal AKI from HRS"
  • "Therapeutic: Expands intravascular volume, binds vasodilators"

Monitoring:

• Daily creatinine
• Clinical assessment for fluid overload (JVP, lung crepitations)
• If creatinine improves → Pre-renal AKI (not HRS)
• If creatinine stable or rises → HRS confirmed

3. Pharmacotherapy: Vasoconstrictor Therapy

The cornerstone of HRS treatment is splanchnic vasoconstriction to redistribute blood from gut to systemic circulation, improving renal perfusion.

First-Line: Terlipressin + Albumin

Terlipressin (Vasopressin analogue):

• Mechanism: V1 receptor agonist → splanchnic vasoconstriction
• Dose Regimens:
  • "Intermittent: 1 mg IV bolus Q4-6h initially"
    • If no response after 3 days, increase to 2 mg Q4-6h
  • "Continuous infusion: 2-12 mg/day (better tolerated, fewer ischaemic complications) [18]"
• Duration: Continue until HRS reversal (Cr less than 1.5 mg/dL or less than 133 μmol/L) or maximum 14 days
• Always combine with albumin: 20-40 g/day IV

Evidence:

• CONFIRM Trial (NEJM 2021): Terlipressin + albumin vs albumin alone in North America [4]
  • "HRS reversal: 32% vs 17% (p=0.006)"
  • Led to FDA approval (only approved vasoconstrictor in US)
• Meta-analyses: Terlipressin improves HRS reversal (OR 3.5-4.0) and short-term survival [19]

Contraindications:

• Absolute:
  • Severe coronary artery disease (recent MI, unstable angina)
  • Severe peripheral vascular disease
  • Pregnancy
• Relative:
  • Arrhythmias
  • Heart failure
  • Mesenteric ischaemia

Adverse Effects:

• Ischaemic complications (10-15%): Myocardial ischaemia, mesenteric ischaemia, digital ischaemia/gangrene, skin necrosis [4]
• Monitoring: Daily ECG, peripheral pulse checks, abdominal pain assessment
• Continuous infusion reduces ischaemic risk vs bolus dosing

Alternative: Noradrenaline + Albumin

Noradrenaline:

• Dose: 0.5-3 mg/hour IV (titrate to MAP > 10 mmHg increase)
• Setting: ICU only (requires central line, invasive monitoring)
• Evidence: Non-inferior to terlipressin for HRS reversal [20]
• Advantages: Lower cost, better availability, fewer ischaemic complications
• Disadvantages: Requires ICU, cannot be used on general ward

When to Use:

• Patient already in ICU
• Terlipressin contraindicated or unavailable
• Concurrent septic shock (noradrenaline also treats shock)

Second-Line: Midodrine + Octreotide + Albumin

Less Effective Alternative:

• Midodrine (oral α1-agonist): 7.5 mg PO TDS (max 15 mg TDS)
• Octreotide (somatostatin analogue): 100-200 μg SC TDS
• Albumin: 20-40 g/day IV
• Evidence: Lower reversal rates (25-30%) compared to terlipressin [21]
• Use: Only if terlipressin/noradrenaline unavailable or contraindicated

4. Renal Replacement Therapy (RRT)

Indications:

• Vasopressor therapy contraindicated or ineffective
• Severe uraemia (Cr > 500 μmol/L, symptomatic)
• Refractory hyperkalaemia (K > 6.5 mmol/L)
• Severe metabolic acidosis (pH less than 7.2)
• Pulmonary oedema unresponsive to diuretics

Modality:

• Continuous RRT (CRRT): Preferred in haemodynamically unstable patients
• Intermittent Haemodialysis (IHD): If haemodynamically stable

Prognosis on RRT:

• Does NOT reverse HRS (unlike vasopressors)
• Bridge to transplant or recovery
• High mortality if transplant not achieved
• Some patients recover renal function post-transplant (30-40%)

Complications:

• Haemodynamic instability (worsened by ultrafiltration)
• Bleeding risk (coagulopathy in cirrhosis)
• Infection (dialysis catheter)

5. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Mechanism:

• Creates shunt between portal vein and hepatic vein
• Reduces portal pressure → improves systemic haemodynamics

Evidence:

• More effective for HRS-NAKI (Type 2) than HRS-AKI
• Improves renal function in 60-75% of HRS-NAKI cases [22]
• Limited role in HRS-AKI (too sick to tolerate procedure)

Indications:

• HRS-NAKI with refractory ascites
• Bridge to transplant
• Selected HRS-AKI patients (MELD less than 18, Child-Pugh less than 12, bilirubin less than 5 mg/dL)

Contraindications:

• Severe liver failure (bilirubin > 5 mg/dL)
• Hepatic encephalopathy (Grade 3-4)
• Heart failure
• Sepsis

Complications:

• Hepatic encephalopathy (30-40%)
• TIPS stenosis/thrombosis
• Worsening liver failure

6. Liver Transplantation (Definitive Treatment)

Only Cure for HRS:

• Liver transplant reverses the underlying pathophysiology
• Renal function recovers in 60-80% of HRS patients post-transplant [23]

Transplant Decision: Liver Alone vs Simultaneous Liver-Kidney (SLK)

MELD Exception:

• HRS significantly raises MELD score → higher transplant priority
• Early listing essential (mortality on waitlist 20-40%)

Post-Transplant:

• Immunosuppression nephrotoxicity (calcineurin inhibitors)
• 30-40% develop CKD at 5 years post-transplant

7. Prevention Strategies

Primary Prevention:

• SBP Prophylaxis: Norfloxacin 400mg OD or Ciprofloxacin 500mg OD (if prior SBP or high risk) [9]
• Albumin with SBP treatment: 1.5 g/kg day 1, 1 g/kg day 3 [9]
• Albumin with LVP: 6-8 g/L ascites removed (if > 5L) [12]
• Avoid nephrotoxins: NSAIDs, aminoglycosides
• Judicious diuretic use: Avoid over-diuresis

Secondary Prevention (Prevent Recurrence):

• Continue albumin infusions (40 g twice weekly) [24]
• Midodrine/octreotide maintenance (if responded to vasopressors)
• List for liver transplant urgently

---

8. Complications

Complications of HRS Itself

Complications of Treatment

Terlipressin:

• Ischaemic Complications (10-15%): [4]
  • Myocardial ischaemia/infarction (5%)
  • Mesenteric ischaemia (2%)
  • Digital ischaemia/gangrene (2-3%)
  • Skin necrosis
• Prevention: Continuous infusion preferred over bolus, daily monitoring (ECG, peripheral pulses)
• Management: Stop terlipressin immediately if ischaemia suspected

Albumin Infusion:

• Fluid Overload: Pulmonary oedema (10-15%)
  • "Risk factors: Pre-existing heart failure, rapid infusion"
  • "Monitor: Respiratory rate, oxygen saturations, lung auscultation"
  • "Management: Slow infusion rate, consider diuretics if euvolaemic"

Renal Replacement Therapy:

• Haemodynamic Instability: Hypotension during dialysis
• Bleeding: Anticoagulation + coagulopathy
• Infection: Dialysis catheter-related (CRBSI)

---

9. Prognosis and Outcomes

Natural History (Untreated)

Outcomes with Vasoconstrictor Therapy

HRS Reversal Rates: [4,19]

• Complete Response (Cr less than 1.5 mg/dL): 40-50% with terlipressin + albumin
• Partial Response: Additional 20-30%
• Non-Response: 20-30%

Survival:

• If HRS Reversal: 3-month survival 60-70% (vs 20-30% without reversal)
• Recurrence: Common (20-30%) after stopping vasopressors
• Definitive cure requires transplantation

Predictors of Response:

Post-Transplant Outcomes

Renal Recovery:

• 60-80% of HRS patients recover renal function post-liver transplant [23]
• Recovery may take weeks to months
• 20-40% require temporary RRT post-transplant

Long-Term Renal Function:

• 30-40% develop CKD at 5 years (immunosuppression nephrotoxicity)
• SLK recipients have better long-term renal outcomes but higher surgical risk

Survival:

• 1-year survival: 80-85% (similar to non-HRS transplant recipients if HRS reversed)
• 5-year survival: 70-75%
• Pre-transplant HRS reversal improves post-transplant outcomes

---

10. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. CONFIRM Trial (Wong et al., NEJM 2021): [4]

• Design: RCT, terlipressin + albumin vs placebo + albumin (300 patients, North America)
• Results: HRS reversal 32% vs 17% (p=0.006)
• Impact: FDA approval of terlipressin (first approved HRS drug in US)

2. Albumin in SBP (Sort et al., NEJM 1999): [9]

• Design: RCT, cefotaxime + albumin vs cefotaxime alone (126 patients)
• Results: Renal impairment 10% vs 33% (pless than 0.001); in-hospital mortality 10% vs 29% (p=0.01)
• Impact: Albumin now standard of care in SBP

3. Terlipressin Meta-Analysis (Nassar et al., J Hepatol 2021): [19]

• Design: Meta-analysis of 14 RCTs (1,017 patients)
• Results: HRS reversal OR 4.27 (95% CI 2.98-6.13); reduced mortality
• Caveat: Ischaemic adverse events in 10-15%

4. Noradrenaline vs Terlipressin (Sharma et al., Gastroenterology 2008): [20]

• Design: RCT (46 patients)
• Results: HRS reversal 40% vs 43% (non-significant difference)
• Impact: Noradrenaline valid alternative (especially in ICU)

5. Albumin Maintenance (Caraceni et al., Lancet 2018): [24]

• Design: RCT, albumin 40g twice weekly vs standard care (431 patients)
• Results: Reduced ascites, infections, and mortality (38% vs 48% at 18 months)
• Controversy: High cost; not universally adopted

Evolving Evidence

Areas of Active Research:

• New Vasoconstrictors: Serelaxin (failed trial), vasopressin analogues
• Biomarkers: NGAL, cystatin C for early HRS prediction
• Artificial Liver Support: MARS (Molecular Adsorbent Recirculating System) - limited evidence
• Stem Cell Therapy: Experimental; no proven benefit
• Combination Therapy: TIPS + vasopressors

---

11. Patient and Layperson Explanation

What is Hepatorenal Syndrome?

Hepatorenal Syndrome (HRS) is kidney failure that happens in people with severe liver disease (cirrhosis). The kidneys themselves are actually healthy — if we took them out and put them in a person with a healthy liver, they would work perfectly. The problem is that the sick liver causes changes in blood flow that starve the kidneys of blood.

Why does the liver affect the kidneys?

When the liver is badly scarred (cirrhosis), it causes high pressure in the veins draining the gut. This makes blood vessels in the belly area expand and fill with blood. The body thinks it's running low on blood (even though there's actually plenty), so it tries to "save" blood by tightening up blood vessels everywhere else — including in the kidneys. When the kidney blood vessels squeeze shut, the kidneys stop working.

What are the symptoms?

You might not notice symptoms from the kidney failure itself at first. Most people already have symptoms from liver disease, like:

• Swollen belly (fluid buildup called ascites)
• Yellow skin and eyes (jaundice)
• Confusion
• Reduced urine output

The kidney failure is usually discovered on blood tests.

How serious is it?

HRS is very serious. Without treatment, most people with acute HRS (HRS-AKI) survive only 2-4 weeks. Even with treatment, it's difficult to reverse, and the only real cure is a liver transplant. However, modern drugs can reverse HRS in about half of cases, which buys time to get a transplant.

How is it treated?

1. Find and fix triggers: If an infection (like infected belly fluid) caused the HRS, we treat that first.

2. Special medications:

• Terlipressin: A drug that squeezes the blood vessels in the belly, pushing blood back to the kidneys
• Albumin: A protein solution that helps keep fluid in blood vessels

These are given through a drip in hospital for 1-2 weeks.

3. Dialysis: If the kidneys are very bad or the drugs don't work, you might need temporary dialysis.

4. Liver Transplant: This is the only cure. A new liver fixes the blood flow problem, and the kidneys usually start working again.

Will the kidneys recover?

• With drug treatment: About 40-50% of people have kidney function improve
• After liver transplant: 60-80% of people recover kidney function within weeks to months
• Some people need both a liver AND kidney transplant if the kidneys have been damaged too long

What can I do?

• Avoid medications that harm kidneys (like ibuprofen, naproxen)
• Don't wait to seek medical help if you have liver disease and feel unwell
• If you have HRS, getting listed for liver transplant quickly is essential

---

12. Examination Focus

Common Exam Questions (MRCP, FRACP, PLAB)

1. Diagnosis:

• Q: "A 56-year-old man with alcoholic cirrhosis develops rising creatinine despite IV fluids. Urine sodium is 8 mmol/L. Diagnosis?"
  • "A: Hepatorenal Syndrome (HRS-AKI). Low urine Na (less than 10) suggests avid renal Na retention. Lack of response to fluids excludes pre-renal AKI."

2. Treatment:

• Q: "First-line treatment for HRS-AKI?"
  • "A: Terlipressin + Albumin. (Noradrenaline + albumin if in ICU is also acceptable.)"

3. Investigations:

• Q: "Investigation to distinguish HRS from ATN?"
  • "A: Urine sodium and FeNa. HRS: Urine Na less than 10 mmol/L, FeNa less than 1%. ATN: Urine Na > 20 mmol/L, FeNa > 2%."

4. Diagnostic Criteria:

• Q: "What must you do before diagnosing HRS?"
  • "A: "
    1. Stop diuretics and nephrotoxins
    2. Give albumin 1 g/kg/day × 2 days
    3. If creatinine does not improve → HRS
    4. Exclude structural kidney disease (proteinuria less than 500mg, normal renal US)

5. Contraindications:

• Q: "Contraindication to terlipressin?"
  • "A: Severe coronary artery disease, recent MI, peripheral vascular disease (risk of ischaemic complications)."

6. SBP Prevention:

• Q: "How does albumin prevent HRS in SBP?"
  • "A: Albumin (1.5 g/kg day 1, 1 g/kg day 3) with antibiotics reduces HRS incidence from 30% to 10% by maintaining intravascular volume and binding vasodilators."

Viva Points (Oral Exam Scenarios)

Viva Point: Opening Statement: "Hepatorenal Syndrome is functional renal failure occurring in patients with advanced cirrhosis and ascites, caused by severe renal vasoconstriction in the setting of splanchnic vasodilation. It is classified as HRS-AKI (acute, formerly Type 1) or HRS-NAKI (non-acute, formerly Type 2). It is a diagnosis of exclusion requiring failure to respond to volume expansion with albumin."

Pathophysiology Explanation: "In cirrhosis, portal hypertension causes massive splanchnic vasodilation via nitric oxide and other mediators. Blood pools in the gut circulation, reducing effective arterial blood volume. The body activates compensatory systems — RAAS, sympathetic nervous system, and ADH — causing systemic vasoconstriction. The kidneys are caught in this response, with intense afferent arteriole vasoconstriction leading to reduced GFR. Critically, the kidneys are structurally normal; if transplanted into a patient with a healthy liver, they function perfectly."

Management Approach: "Management follows a stepwise approach:

1. Identify and treat precipitants, especially SBP — give cefotaxime plus albumin
2. Stop all diuretics and nephrotoxic drugs
3. Volume expansion trial with albumin 1 g/kg/day for 2 days — if no improvement, HRS is confirmed
4. Initiate vasoconstrictor therapy: Terlipressin (1-2 mg IV Q4-6h) plus albumin (20-40 g/day), aiming for creatinine reversal to below 1.5 mg/dL
5. List urgently for liver transplantation, which is the only definitive cure
6. Consider RRT if vasopressors fail or are contraindicated, as a bridge to transplant"

Key Evidence: "The CONFIRM trial in NEJM 2021 showed terlipressin plus albumin reverses HRS in 32% vs 17% with albumin alone, leading to FDA approval. Sort's 1999 trial showed albumin with antibiotics in SBP reduces HRS from 33% to 10%. Noradrenaline is non-inferior to terlipressin in ICU settings."

Common Mistakes

❌ Diagnosing HRS without volume expansion trial

• Must give albumin 1 g/kg × 2 days and demonstrate no response

❌ Using terlipressin in patient with recent MI

• Terlipressin causes vasoconstriction → can precipitate myocardial ischaemia

❌ Forgetting albumin with terlipressin

• Terlipressin alone is less effective; ALWAYS combine with albumin

❌ Giving NSAIDs or ACE inhibitors in cirrhosis

• NSAIDs block renal prostaglandins → precipitate HRS
• ACE inhibitors worsen hypotension and GFR

❌ Not screening for SBP

• SBP is the most common trigger; diagnostic paracentesis is mandatory

❌ Assuming high urine sodium means HRS

• High urine Na (> 20) suggests ATN, NOT HRS (HRS has urine Na less than 10)

Model Answers

Q: Describe your approach to AKI in a patient with cirrhosis and ascites

Model Answer: "I would approach this systematically using a structured framework:

Initial Assessment:

• History: Identify precipitants (recent infection, GI bleed, diuretic use, nephrotoxic drugs)
• Examination: Volume status, signs of sepsis, stigmata of chronic liver disease
• Baseline tests: Creatinine, urea, electrolytes, FBC, LFTs, coagulation

Immediate Management:

1. Stop diuretics and nephrotoxic medications (NSAIDs, aminoglycosides)
2. Screen for infection:
   • Diagnostic paracentesis (SBP): Neutrophils > 250 = treat with cefotaxime + albumin
   • Blood and urine cultures
3. Volume expansion trial: Albumin 1 g/kg/day for 2 days (max 100g/day)

Differential Diagnosis:

• Pre-renal AKI (responds to volume expansion)
• HRS (no response to albumin)
• ATN (urine Na > 20, muddy brown casts)
• Intrinsic renal disease (proteinuria > 500mg, haematuria)
• Obstruction (check renal ultrasound)

If HRS Diagnosed (creatinine does not improve after albumin trial):

• Check ICA-AKI criteria met (no shock, no nephrotoxins, no structural disease)
• Initiate terlipressin 1-2mg IV Q4-6h plus albumin 20-40g/day
• Monitor for response (daily creatinine, target less than 1.5 mg/dL)
• Check for terlipressin complications (ECG, peripheral pulses)
• List urgently for liver transplant
• Consider RRT if vasopressors fail or contraindicated

Follow-Up:

• If HRS reverses: Continue monitoring, prevent recurrence (albumin infusions, transplant listing)
• If no response: Discuss prognosis, transplant suitability, or palliative care options"

---

13. References

Primary Sources

1. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279-1290. doi:10.1056/NEJMra0809139

2. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811-822. doi:10.1016/j.jhep.2019.07.002

3. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-1318. doi:10.1136/gut.2006.107789

4. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome (CONFIRM). N Engl J Med. 2021;384(9):818-828. doi:10.1056/NEJMoa2008290

5. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968-974. doi:10.1016/j.jhep.2014.12.029

6. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105(1):229-236. doi:10.1016/0016-5085(93)90031-7

7. Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4(11):1385-1394. doi:10.1016/j.cgh.2006.08.007

8. Arroyo V, Moreau R, Jalan R, Ginès P. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. J Hepatol. 2015;62(1 Suppl):S131-143. doi:10.1016/j.jhep.2014.11.045

9. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409. doi:10.1056/NEJM199908053410603

10. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51(2):576-584. doi:10.1002/hep.23286

11. Cardenas A, Ginès P. Acute-on-chronic liver failure: the kidneys. Curr Opin Crit Care. 2011;17(2):184-189. doi:10.1097/MCC.0b013e328344b3da

12. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172-1181. doi:10.1002/hep.24786

13. Allegretti AS, Parada XV, Endres P, et al. Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: A prospective study. Clin Transl Gastroenterol. 2021;12(5):e00359. doi:10.14309/ctg.0000000000000359

14. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151-1157. doi:10.1002/hep.1840080532

15. Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients. J Hepatol. 2012;56 Suppl 1:S13-24. doi:10.1016/S0168-8278(12)60003-8

16. Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med. 1969;280(25):1367-1371. doi:10.1056/NEJM196906192802501

17. Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60(2):622-632. doi:10.1002/hep.27173

18. Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology. 2016;63(3):983-992. doi:10.1002/hep.28396

19. Nassar Junior AP, Farias AQ, D'Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107466. doi:10.1371/journal.pone.0107466

20. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103(7):1689-1697. doi:10.1111/j.1572-0241.2008.01828.x

21. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742-748. doi:10.1007/s10620-006-9312-6

22. Song T, Rössle M, He F, Liu F, Guo X, Qi X. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis. 2018;50(4):323-330. doi:10.1016/j.dld.2018.01.123

23. Northup PG, Sundaram V, Fallon MB, et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost. 2008;6(1):2-9. doi:10.1111/j.1538-7836.2007.02772.x

24. Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417-2429. doi:10.1016/S0140-6736(18)30840-7

25. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024

26. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087-2107. doi:10.1002/hep.22853

27. Piano S, Tonon M, Angeli P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin Mol Hepatol. 2021;27(3):437-445. doi:10.3350/cmh.2020.0329

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and be made in consultation with appropriate specialists. Always refer to local guidelines and protocols.